Added to basket
Unapplied Changes
Purasome Skin Glow Complex (SGC100+) has been developed with dull, uneven, and compromised skin in mind. The complex contains exosomes sourced ethically from bovine colostrum, the structural and functional stability of which supports the repair of skin damage caused by UV exposure. The most common way to apply this product has historically been through microneedling, however, this case study evaluates the efficacy of topical application in improving skin appearance, specifically the reduction of inflammation and congestion.
Background
The stimulation of fibroblasts is at the core of the utility of exosomes derived from bovine colostrum, which have been proven to improve skin quality through stimulating collagen production. Additionally, exosomes may contain immunomodulatory proteins which prevent overactivity in the immune system, regulating responses and reducing inflammation. SGC100+ is therefore well situated to treat congested and inflamed skin—the secretomes, cytokines, and growth factors found within promote cell turnover and accelerate blood vessel formation, which facilitate skin healing and further decrease inflammation; in particular, cytokines contribute to inflammation control by regulating the body’s immune response.
Methodology
The patient is a 19-year-old woman with skin type II on the Fitzpatrick scale. Her primary concerns were compromised barrier function, breakouts, and redness. Prior to her A-levels and university applications, the patient had very clear skin. However, around this stressful period she developed acne and increased redness. This persisted and worsened over a two year period and was likely stress related. Initially, the patient pursued a traditional dermatology route, topically applying 0.02% tretinoin and 0.1% Differin to the affected area, accompanied by 100mg of oral Doxycycline. This was found to be ineffective.
After eight weeks on these medications, the breakouts and compromised barrier function persisted. As a result, the topical application of SGC100+ was introduced. The complex comprises of: 200mg of 20 growth factors; 20 billion exosomes derived from bovine colostrum; 50mg of high molecular weight hyaluronic acid (1100-1400kDA); 55mg of low molecular weight hyaluronic acid (80-100kDA); plant-derived seed stem cells; antioxidants; and peptides.
The patient applied SGC100+ 0.5mls topically every day for their fi rst month: it was applied in the morning and the evening onto clean, dry skin. For the first week, the patient applied SGC100+ in combination with tretinoin and Differin, which were subsequently stopped, as tretinoin caused the patient to experience sore skin, and Doxycycline was found to be unsuitable for the patient due to her anaemia.
The stimulation of fibroblasts is at the core of ...exosomes... to improve skin quality through stimulating collagen production
After the first month, the patient reduced the application of 0.5mls of SGC100+ to four days a week for two months, before reducing to 0.5mls of SGC100+ two days a week until she had fi nished the three vials of Purasomes. Throughout her time using SGC100+, the patient reduced her skincare routine to three simple products: an exfoliating cleanser; an oil-free moisturiser containing antimicrobial and anti-redness peptides, mushroom stem cells, and hyaluronic acid; and an SPF. After the fi rst two weeks applying SGC100+, the patient changed the oil-free moisturiser for a more emollient option.
Results
The results were incredibly encouraging: they were assessed using photographic evidence captured at baseline and subsequent intervals, alongside clinical evaluation and patient self-assessment. After beginning to apply Purasome SGC100+, the patient demonstrated a clear, steady improvement in active acne and overall skin condition. By week four, there was a noticeable reduction in inflammation, redness, and lesion count.
On the eighth week, the skin had visibly cleared, with only a few residual pigmental areas left.
Discussion
This case provides a strong example of how topical application of Purasome SGC100+, can provide support to skin prone to breakouts. This is especially pertinent where reducing infl ammation is a key focus, as traditional acne treatments can often cause irritation or fl aking. SGC100+ proved a gentler approach while still delivering compelling results.
It is important to acknowledge the limitations of this case study, including the absence of a control group, reliance on subjective patient self-assessments alongside clinical observations, and the short duration of follow-up. Further controlled studies with larger cohorts are needed.
Conclusion
The outcomes suggest that topical Purasomes such as SGC100+, could be valuable in improving skin quality. The efficacy of this case, where only topical application was utilised, suggests that this method could be especially benefi cial for patients who are sensitive or do not respond positively to harsher treatments.
In this study, the topical application of Purasome SGC100+ led to a signifi cant improvement in the patient’s acne, with visible reduction in redness, infl ammation, and active breakouts. The patient tolerated this treatment well, with the skin responding quickly and positively. That said, the vials are not designed with at-home use in mind.
This, amalgamated with the high cost associated with Purasomes, does not make it the most patient-friendly treatment. Should these barriers be addressed to ensure accessibility, Purasomes may act as a promising alternative or additional treatment for acne, without the irritation which frequently accompanies stronger actives.
.Julie Scott is an Independent Nurse Prescriber and trainer with over 25 years’ experience in the fi eld of plastics and skin rejuvenation, and runs her own clinic in Essex, Facial Aesthetics. Julie is an ambassador for BCAM, JCCP and BDDF and is a co-chair of Wigmore Presents 26.
